Nectar Lifesciences has scheduled its 31st Annual General Meeting for September 18, 2026. The event will be conducted through video conference or other audio-visual means.

The company issued an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure informs shareholders who have not registered email addresses about the availability of the Annual Report for FY26.

Meeting and Voting Schedule

The AGM is set for Friday, September 18, 2026, at 11:00 am IST. Shareholders can participate in remote e-voting during a specific window preceding the meeting. The cut-off date for both the AGM and e-voting is Friday, September 11, 2026.

Document Access

Electronic copies of the AGM Notice and the Annual Report for FY26 have been sent to shareholders with registered email addresses. For those without registered emails, the documents are accessible via weblinks provided in the intimation letter.

The reports are also available on the company’s website and the listing exchanges’ platforms. Shareholders holding physical shares may contact the Registrar and Share Transfer Agent, KFin Technologies Limited, to register their email addresses for future communications.

Nectar Lifesciences reported a consolidated net loss of ₹2,928.85 crore for the financial year ended March 31, 2026 (FY26), a significant deterioration from the net loss of ₹1,136.81 crore in FY25. The financial performance was heavily impacted by the strategic divestment of its core pharmaceutical businesses and substantial losses on investment instruments.

The company's revenue from operations stood at nil for FY26, as it had disposed of its Active Pharmaceutical Ingredients (API) and formulation businesses through a slump sale to Ceph Lifesciences Private Limited. This transaction generated an exceptional gain of ₹1,633.73 crore, which was recognized under discontinued operations. However, this gain was more than offset by a pre-tax loss of ₹5,376.55 crore from discontinued operations and a pre-tax loss of ₹878.70 crore from continuing operations.

A critical drag on profitability was a ₹520.95 crore loss on investments, arising from volatility in capital markets affecting mutual fund instruments deployed by the company. Additionally, other income rose to ₹92.91 crore from ₹18.78 crore in the previous year, primarily driven by interest income of ₹70.40 crore.

Balance Sheet and Capital Structure

Nectar Lifesciences significantly deleveraged during the period, repaying all outstanding borrowings. Total borrowings dropped to nil from ₹5,820.23 crore in FY25. Consequently, the debt-to-equity ratio became non-applicable. Cash and cash equivalents increased substantially to ₹1,081.30 crore from ₹192.20 crore, bolstered by proceeds from the slump sale.

The company completed a buy-back of 3 crore equity shares at ₹27 per share, aggregating ₹810.00 crore, through the tender offer route in January 2026. Following the buyback, the paid-up equity share capital reduced to ₹194.26 crore. Promoter Mr. Sanjiv Goyal holds 24.63% of the equity, while Sanjiv (HUF) holds 22.46%.

Strategic Shift to Real Estate

Following the exit from pharmaceuticals, Nectar Lifesciences amended its object clause to include real estate activities. It acquired 100% of Avensis Exports Private Limited (AEPL) in March 2026, infusing an inter-corporate loan of ₹980.00 million into the subsidiary. The board is currently evaluating opportunities in residential, commercial, and industrial real estate sectors.

Board Appointments and Re-Appointments

The 31st Annual General Meeting (AGM), scheduled for September 18, 2026, will consider several board changes:

• Mr. Sanjiv Goyal: Re-appointment as Chairman & Managing Director, retiring by rotation.
• Dr. Kuldip Kumar Bhasin: Re-appointment as Independent Director for a second five-year term, despite having attained the age of 75 years, citing his expertise in scientific research.
• Dr. Indu Pal Kaur: Re-appointment as Independent Director for a second five-year term.
• Dr. Gunmala Suri: Appointment as Non-Executive Non-Independent Director, bringing over 27 years of experience in academic administration and research.

What the Numbers Show

The company’s financial profile has shifted from an operational manufacturing entity to a holding structure with significant cash reserves and no debt. The ₹520.95 crore investment loss constitutes approximately 17.4% of the total net loss, highlighting the risk associated with deploying surplus cash from asset monetization into volatile capital markets without immediate operational revenue generation. While the slump sale gain provided a one-time boost, the absence of revenue from operations means the company is currently reliant on interest income and potential real estate ventures for future earnings.